Patient outcomes at 3 And 6 months
ascites, fatigue, abdominal pain, toxicity, toxicities, anemia, nausea,, non-segmental, tumors, anorexia
DISEASE PROGRESSION, ASCITES, ADVERSE EVENTS, ANEMIA, TUMORS, ANOREXIA
One patient died of disease progression within 30 days post Y90 and was excluded from the treatment response and toxicity analysis. At 3 months post Y90, objective response was achieved for 26 of the 32 treated tumors (81%). In the segmental group, all 18 (100%) had an objective response, while the non-segmental group only had 8 tumors (57%) for which objective response was achieved (Objective response, complete response, and clinical toxicities over the study period (Bolded p-values denote statistical significance)Treatment-related adverse events (AE) were prevalent, with 23 patients (79%) in the entire cohort experiencing any AE at 3 months and 18 (62%) experiencing any AE at 6 months. However, the majority of AEs were mild (grade 1 or 2): 20 patients (69%%) at 3 months and 14 patients (48%) at 6 months. Grade 3 toxicities were experienced by 3 patients (10%) at 3 months in the entire cohort and 4 participants (14%) of the entire cohort at 6 months. Any grade or severe clinical toxicities were not significantly different between the segmental and non-segmental groups (Table The most common treatment-related mild clinical adverse events were fatigue (14% at 6 months and 7% at 6 months), nausea, vomiting, anorexia (14% at 3 months and 7% at 6 months), and abdominal pain (10% at 3 months and 6 months). There were no severe clinical adverse events at 3 months. At 6 months, 2 patients (7%) experienced grade 3 ascites (Table Treatment-related clinical and biochemical adverse events at 3 and 6 months after Y90 radioembolizationThe most common treatment-related, biochemical, and mild AE at 3 months were decreased platelet count (41%), increased international normalized ratio (34%), and anemia (28%). The grade 3 severe biochemical AE at 3 months were decreased white blood cells (7%), decreased platelet count (3%), and decreased albumin (7%) (Table 